A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease.
暂无分享,去创建一个
M. Masetti | G. Guaraldi | A. D’Avolio | F. di Benedetto | S. Cocchi | M. Codeluppi | R. Espósito | S. Bonora | M. Floridia | S. Baroncelli | A. Bertolini | D. Pinetti | A. Motta | S. Ciaffi
[1] E. Seminari,et al. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. , 2007, The Journal of antimicrobial chemotherapy.
[2] E. Seminari,et al. Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels. , 2007, The new microbiologica.
[3] B. Damle,et al. Pharmacokinetics of Nelfinavir in Subjects With Hepatic Impairment , 2006, Journal of clinical pharmacology.
[4] R. Bertz,et al. Further information on the administration of h2-receptor antagonists with atazanavir. , 2006, Journal of acquired immune deficiency syndromes.
[5] Alessandro Nanni Costa,et al. LIVER TRANSPLANTATION IN HIV-INFECTED INDIVIDUALS: RESULTS OF THE ITALIAN NATIONAL PROGRAM. , 2006 .
[6] J. Torre-Cisneros,et al. Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. , 2006, The Journal of antimicrobial chemotherapy.
[7] S. Brun,et al. Pharmacokinetics of Lopinavir/Ritonavir in HIV/Hepatitis C Virus–Coinfected Subjects With Hepatic Impairment , 2006, Journal of clinical pharmacology.
[8] Patrick F. Smith,et al. Inhibition of Atazanavir Oral Absorption by Lansoprazole Gastric Acid Suppression in Healthy Volunteers , 2006, Pharmacotherapy.
[9] P. Lynch,et al. Elevated Plasma Concentrations of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors in Patients Coinfected with Human Immunodeficiency Virus and Hepatitis B or C: Case Series and Literature Review , 2005, Pharmacotherapy.
[10] C. Farthing,et al. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. , 2005, Journal of acquired immune deficiency syndromes.
[11] R. Bruno,et al. Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. , 2005, AIDS reviews.
[12] Giorgio Palù,et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.
[13] R. Maserati,et al. Clinical Pharmacokinetics of Nelfinavir and Its Metabolite M8 in Human Immunodeficiency Virus (HIV)-Positive and HIV-Hepatitis C Virus-Coinfected Subjects , 2005, Antimicrobial Agents and Chemotherapy.
[14] D. Margolis,et al. Atazanavir for the Treatment of Human Immunodeficiency Virus Infection , 2004, Pharmacotherapy.
[15] V. Soriano,et al. Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients , 2004, HIV clinical trials.
[16] V. Calvez,et al. Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients , 2004, Antimicrobial Agents and Chemotherapy.
[17] M. Sulkowski. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] G. Lüchters,et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection , 2003, The Lancet.
[19] P. Reiss,et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals , 2003, AIDS.
[20] D. Conte,et al. Severe liver fibrosis or cirrhosis: accuracy of US for detection--analysis of 300 cases. , 2003, Radiology.
[21] J. Macías,et al. Mortality due to Liver Failure and Impact on Survival of Hepatitis Virus Infections in HIV-Infected Patients Receiving Potent Antiretroviral Therapy , 2002, European Journal of Clinical Microbiology and Infectious Diseases.
[22] D. Snydman,et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] D. Bulman,et al. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. , 2000, British journal of clinical pharmacology.
[24] B. Sadler,et al. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function , 2000, Antimicrobial Agents and Chemotherapy.
[25] J. Izopet,et al. Increased Incidence of Indinavir Nephrolithiasis in Patients with Hepatitis B or C Virus Infection , 2000, Antiviral therapy.
[26] V. Rodighiero. Effects of Liver Disease on Pharmacokinetics , 1999, Clinical pharmacokinetics.
[27] R. Maserati,et al. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. , 1999, AIDS.
[28] P. Bedossa,et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. , 1999, Journal of hepatology.
[29] R. Branch. Drugs in liver disease , 1998, Clinical pharmacology and therapeutics.
[30] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[31] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[32] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[33] L. Williams,et al. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[34] Cirrhosis: Diagnosis with Sonographic Study of the Liver Surface , 1989 .
[35] J. Gerber,et al. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] M. Brodie,et al. Drug metabolism in liver disease. , 1989, Pharmacology & therapeutics.